NCT03747484View on ClinicalTrials.gov

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions
Other Skin
Interventions
BIOLOGICAL

Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR

Given IV

DRUG

Avelumab

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

BIOLOGICAL

Interferon Gamma-1b

Given SC

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Affini-T Therapeutics, Inc.

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER